Zydus Lifesciences Limited has informed the Exchange regarding a press release dated February 04, 2026, titled "Zydus receives tentative approval from USFDA for Dapagliflozin Tablets, 5 mg and 10 mg".
ZYDUSLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Zydus Lifesciences has received tentative approval from the US Food and Drug Administration (USFDA) for Dapagliflozin Tablets in 5 mg and 10 mg strengths. Dapagliflozin is a generic version of Farxiga, used to treat type-2 diabetes, heart failure, and chronic kidney disease. A tentative approval means the drug meets all USFDA quality, safety, and efficacy standards but cannot be launched in the US market until existing patents or exclusivity periods expire. This adds to Zydus's growing portfolio of approved generic products targeting the US market, which is a key growth driver for the company.
Positive for Zydus's US generics pipeline and long-term revenue potential, though this approval alone will not immediately boost sales. Actual revenue impact will depend on when patent hurdles are cleared and the competitive landscape at launch.